ERBB2 and neoplasm: A higher percentage of tumour heterogeneity was noted by Buza et al. in 2013 who has observed a significant tumour heterogeneity in HER2 protein expression in 20 out of 38 cases (53%) of endometrial serous carcinoma [13].